Abstract:Rationale: Eosinophilic granulomatosis with polyangiitis (EGPA) is belongs to the antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) subgroups. EGPA, unlike other subgroups of AAV, including microscopic polyangiitis (MPA) and granulomatosis with polyangiitis, has the unique feature that both ANCA and eosinophilic inflammation are involved in its pathogenesis. Although AAV often relapses, there are currently no reports of EGPA developing during other subgroups of AAV. Herein, we document a case of EGPA that developed during the clinical course of MPA. Patient concerns: A 61-year-old Japanese woman was diagnosed with MPA based on interstitial lung disease and myeloperoxidase-ANCA positivity. After starting immunosuppression therapy, including prednisolone and tacrolimus, she was expected to achieve clinical remission. Nonetheless, she occasionally experienced MPA relapse, which required an increased prednisolone dose, rituximab, intravenous cyclophosphamide, and plasma exchange. Three years after MPA onset, she developed renal amyloidosis; thus, subcutaneous tocilizumab was added to her regimen. Following clinical remission, the administration interval of her subcutaneous tocilizumab therapy was extended and immunosuppressants were discontinued. She then developed bronchial asthma and mild eosinophilia (eosinophilic count: ~1000/μL). Further, a year later, she underwent total hip replacement using a titanium implant. Subsequently, she developed abnormal sensation in both hands, numbness, and muscle weakness, as well as palpable purpura and massive eosinophilia (eosinophilic count: ~8500/μL). Diagnosis: We diagnosed the patient with EGPA based on 5 items (asthma, multiple mononeuropathies, sinus abnormality, and extravascular eosinophils) of the 1990 American College of Rheumatology classification criteria. Interventions: We administered 400 mg/kg intravenous immunoglobulin for 5 consecutive days, 300 mg mepolizumab subcutaneously every 4 weeks, and 40 mg/day prednisolone following pulsed methylprednisolone therapy (1000 mg/day for 3 consecutive days). Outcomes: After these treatments, the patient's symptoms improved, and eosinophilic count and inflammatory markers declined. Lessons: The present case suggests that EGPA can be induced by the development of eosinophilic inflammation in other subgroups of AAV.

The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion

Eosinophil Infiltration and Activation in Nasal Polyposis.

A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis

Therapeutic advances in eosinophilic granulomatosis with polyangiitis

Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report

[Eosinophilic granulomatosis with polyangiitis: a review article]

Eosinophilic granulomatosis with polyangiitis: A review

Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis

Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment

Predictors of new-onset EGPA in patient with severe asthma treated with anti IL-4/13

Genetic and Non-Genetic Contributions to Eosinophilic Granulomatosis with Polyangiitis: Current Knowledge and Future Perspectives

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis

HES and EGPA: Two Sides of the Same Coin

From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis

Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis

Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review

The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma

Eosinophils in Health and Disease: A State-of-the-Art Review

Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis